Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review.

MLA

McGregor, Bradley, et al. “Management of Adverse Events Associated with Cabozantinib plus Nivolumab in Renal Cell Carcinoma: A Review.” Cancer Treatment Reviews, vol. 103, Feb. 2022, p. 102333. EBSCOhost, https://doi.org/10.1016/j.ctrv.2021.102333.

APA

McGregor, B., Mortazavi, A., Cordes, L., Salabao, C., Vandlik, S., & Apolo, A. B. (2022). Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. Cancer Treatment Reviews, 103, 102333. https://doi.org/10.1016/j.ctrv.2021.102333

Chicago

McGregor, Bradley, Amir Mortazavi, Lisa Cordes, Cristina Salabao, Susan Vandlik, and Andrea B Apolo. 2022. “Management of Adverse Events Associated with Cabozantinib plus Nivolumab in Renal Cell Carcinoma: A Review.” Cancer Treatment Reviews 103 (February): 102333. doi:10.1016/j.ctrv.2021.102333.